Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
13 September 2021Big PharmaBen Wodecki

Bausch settles $300m antitrust case over diabetes drug price hikes

Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza (metformin hcl).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More on this story

Generics
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13 December 2021   Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory